NEW YORK (GenomeWeb News) – Cisbio Bioassays today announced a deal to distribute BellBrook Labs' Transcreener Epigen Methyltransferase assay.
Under the terms of the agreement, the second distribution deal between the companies, Cisbio will offer the assay for epigenetics-based drug discovery studies conducted by pharmaceutical and biotechnology researchers in the US, Europe, and Asia.
Transcreener Epigen Methyltransferase is a universal detection method based on Transcreener AMP/GMP assay technology developed by BellBrook that involves coupling enzymes for detection of methyltransferase reaction products. The products are crucial targets in epigenetics research, the partners said.
Financial and other terms of the deal were not disclosed.
In 2008 Cisbio and BellBrook teamed up to launch HTRF Transcreener ADP, an assay for the high-throughput screening and profiling of kinases.